India's Vaccine Manufacture Intends to Produce 200 Million Doses

On September 29, 2020, an expanded collaboration was announced among the Serum Institute of India (SII), Gavi, and the Bill & Melinda Gates Foundation to accelerate the manufacture and delivery of up to an additional 100 million doses of safe and effective COVID-19 vaccines for low- and middle-income countries. This expansion brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation to an aggregate of up to 200 million doses.

SII stated it 'intends to manufacture COVID-19 preventive vaccines licensed from AstraZeneca and Novavax if they are successful in attaining full licensure and WHO Prequalification.'